The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. announced that its investigational therapy OCU410, when administered at a medium dose, led to a 31 percent reduction in geographic atrophy (GA) lesion growth in phase 2 clinical trials.
The update also indicates a 27 percent enhancement in ellipsoid zone (EZ) preservation for patients treated with the medium dose compared to control, supporting the selection of this dosage as optimal for upcoming phase 3 studies. Geographic atrophy is an advanced form of age-related macular degeneration that can result in vision loss. The latest corporate presentation on this progress is available on Ocugen, Inc.'s website.
Ocugen has accelerated development of modifier gene therapies to treat major blindness diseases, according to a previous update from the company’s pipeline initiatives (link). The company is also advancing gene therapies intended to address hundreds of mutations linked to a global vision loss burden estimated at $132 billion (link). These efforts place Ocugen among key developers in the ophthalmic gene therapy space.